Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03650361
Recruitment Status : Completed
First Posted : August 28, 2018
Last Update Posted : April 26, 2019
Sponsor:
Collaborator:
Catawba Research, LLC
Information provided by (Responsible Party):
Aleor Dermaceuticals Limited

Brief Summary:
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Adapalene Gel 0.3% Drug: Differin 0.3% Topical Gel Drug: Adapalene Gel 0.3% Vehicle Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 755 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double (Participant, Investigator)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Actual Study Start Date : September 17, 2018
Actual Primary Completion Date : February 16, 2019
Actual Study Completion Date : February 16, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne
Drug Information available for: Adapalene

Arm Intervention/treatment
Experimental: Test Product
Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
Drug: Adapalene Gel 0.3%
Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days

Active Comparator: Reference Product
Adapalene Gel 0.3%, , applied for 84 days
Drug: Differin 0.3% Topical Gel
Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days

Placebo Comparator: Placebo Control
Vehicle of the test product, applied for 84 days
Drug: Adapalene Gel 0.3% Vehicle Placebo
Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days




Primary Outcome Measures :
  1. Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) and in the non-inflammatory (open and closed comedones) lesion counts [ Time Frame: 12 weeks ]
    Uses both modified intent-to-treat (mITT) and per protocol (PP) populations


Secondary Outcome Measures :
  1. The secondary endpoint is the Investigator Global Assessment (IGA) score, expressed in terms of treatment success or failure. [ Time Frame: 12 weeks ]
    Uses both modified intent-to-treat (mITT) and per protocol (PP) populations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.
  • Subjects who are 18 years of age or older (up to the age of 40 inclusive) must have provided IRB approved written informed consent. Subjects ages 12 to 17 years of age inclusive must have provided IRB approved written assent; this written assent must be accompanied by an IRB approved written informed consent from the Subject's legally acceptable representative (i.e., parent or guardian). In addition, all Subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a HIPAA authorization.
  • Subjects must have a minimum ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20 inflammatory lesions (i.e., papules and pustules) and ≤ 2 nodulocystic lesions (i.e., nodules and cysts), at baseline on the face. For the purposes of study treatment and evaluation, these lesions should be limited to the facial treatment area. When counting facial acne lesions, it is important that all lesions be counted, including those present on the nose. Lesions involving the eyes, lip and scalp should be excluded from the count. Subjects may have acne lesions on other areas of the body which will also be excluded from the count, treatment, and the Investigator's Global Assessment (IGA) evaluation (e.g., on the back, chest and arms).
  • Subjects must have a definite clinical diagnosis of acne vulgaris of severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA)
  • Subjects must be willing to refrain from using all other topical acne medications or antibiotics during the 12-week treatment period for acne vulgaris, other than the Investigational Product.
  • Female Subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (stabilized for at least 3 months); NuvaRing® (vaginal contraceptive); Implanon™ (contraceptive implant) double barrier methods (e.g. condom and spermicide); IUD, or abstinence. If a subject who was abstinent becomes sexually active during the study, a 2nd acceptable method of birth control should be documented. A sterile sexual partner is NOT considered an adequate form of birth control. Hormonal contraceptives should not be initiated or changed during the study.
  • All male Subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug. Abstinence is an acceptable method of birth control. Female partners should use an acceptable method of birth control as described in the above Item Number 6.
  • Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.
  • Subjects must be in good health and free from any clinically significant disease, including but not limited to, conditions that may interfere with the evaluation of acne vulgaris. Such conditions include, but are not limited to the following: auto immune disease, rosacea; seborrheic dermatitis; perioral dermatitis; corticosteroid-induced acne; carcinoid syndrome; mastocytosis; acneiform eruptions caused by make-up, medication, facial psoriasis and facial eczema.
  • Subjects who use make-up must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to not change make-up brand/type or frequency of use throughout the study.

Exclusion Criteria:

  • Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
  • Subjects with a history of hypersensitivity or allergy to adapalene, retinoids and/or any of the study medication ingredients, have a known hypersensitivity to adapalene and its excipients.
  • Subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
  • Subjects with excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
  • Subjects who have performed wax depilation of the face within 14 days prior to baseline.
  • Subjects who have used within 6 months prior to baseline or use during the study of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  • Subjects who have used estrogens or oral contraceptives for less than 3 months prior to baseline; use of such therapy must remain constant throughout the study.
  • Subjects who have used any of the following procedures on the face within 1 month prior to baseline or during the study :

    1. cryodestruction or chemodestruction,
    2. dermabrasion,
    3. photodynamic therapy,
    4. acne surgery,
    5. intralesional steroids, or
    6. X-ray therapy.
  • Subjects who have used any of the following treatments within 1 month prior to baseline or during the study:

    1. systemic steroids,
    2. systemic antibiotics,
    3. systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or
    4. systemic anti-inflammatory agents.
  • Subjects who have used any of the following treatments within 2 weeks prior to baseline or during the study:

    1. topical steroids,
    2. topical retinoids,
    3. α-hydroxy/glycolic acid,
    4. benzoyl peroxide, or any other topical acne treatments including over-the-counter preparations
    5. topical anti-inflammatory agents, or
    6. topical antibiotics.
  • Use of spironolactone within 1 month before Screening/Baseline.
  • Subjects who have received radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline.
  • Subjects who have unstable medical disorders that are clinically significant or life-threatening diseases.
  • Subjects who have on-going malignancies requiring systemic treatment will be excluded from study participation. In addition, Subjects who have any malignancy of the skin of the facial area will be excluded.
  • Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or cold.
  • Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to cannabinoids, cocaine and barbiturates).
  • Subjects who have participated in an investigational drug study (i.e., Subjects have been treated with an Investigational Drug) within 30 days prior to baseline will be excluded from study participation. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion.
  • Subjects who have been previously enrolled in this study.
  • Subjects who had laser therapy, electrodessication and phototherapy (e.g., ClearLight®) to the facial area within 1 month prior to study entry.
  • Subjects who had cosmetic procedures (e.g., facials) which may affect the efficacy and safety profile of the Investigational Product within 14 days prior to study entry. Cosmetic procedures and facials are prohibited throughout the study
  • Subjects who currently have or have recently had bacterial folliculitis on the face.
  • Subjects with a baseline irritation score of 3 (severe, marked/intense) for erythema, dryness, burning/stinging, erosion, edema, pain and itching will not be enrolled.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03650361


Locations
Layout table for location information
United States, California
Unison Center for Clinical Trials
Sherman Oaks, California, United States, 91403
United States, Florida
Moore Clinical Research Institute, Inc.
Brandon, Florida, United States, 33511
FXM Research Corp.
Miami, Florida, United States, 33175
FXM Research Miramar
Miramar, Florida, United States, 33027
Moore Clinical Research Institute, Inc.
Tampa, Florida, United States, 33609
Moore Clinical Research Institute, Inc.
Tampa, Florida, United States, 33618
United States, North Carolina
Dermatology Consulting Services, PLLC
High Point, North Carolina, United States, 27262
United States, Texas
3A Research, LLC
El Paso, Texas, United States, 79902
3A Research, LLC
El Paso, Texas, United States, 79925
Belize
FXM Research International
Belize City, Belize
Sponsors and Collaborators
Aleor Dermaceuticals Limited
Catawba Research, LLC
Investigators
Layout table for investigator information
Study Director: Venkata. K. R. CH. Hemanth Varma. P Aleor Dermaceuticals Limited

Layout table for additonal information
Responsible Party: Aleor Dermaceuticals Limited
ClinicalTrials.gov Identifier: NCT03650361     History of Changes
Other Study ID Numbers: ADPG 1807
First Posted: August 28, 2018    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Adapalene
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents